Search

everythinglearnresearchcommunity

for

Search:↓

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Ocrelizumab may cause pancreatitis in some patients.

Hair samples can reliably monitor tacrolimus levels in kidney transplant patients.

Herpes gestationis is linked to certain antigens, atopic eczema affects T cell populations and may be eased by breastfeeding, higher doses of anti-androgen treatment can improve androgenic alopecia, topical minoxidil increases hair thickness, long-term methotrexate therapy can cause liver fibrosis in psoriasis patients, and Lichen Sclerosus et Atrophicus patients aren't at higher risk for autoimmune disorders.

Cells from the lower part of hair follicles are a promising, less invasive option for immune system therapies.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Antihepcidin antibodies may treat inflammation-induced anemia by improving iron metabolism.

COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.

Combining systemic steroids and dithranol can effectively regrow hair in severe alopecia areata.

A woman experienced severe side effects from a drug due to a specific genetic variation, suggesting genetic testing could prevent such risks.

Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

Thymectomy and high-dose prednisolone improved hair loss in a woman with alopecia areata.

Sintilimab treatment caused hair loss but led to complete tumor remission.

A new treatment using a special gel with miR-665 reduces inflammation and helps hair regrow in alopecia areata.

Upadacitinib effectively treats psoriasis and lichen planus together.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.

Restoring immune privilege in hair follicles could help treat certain types of hair loss.

Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

Ectoin helps prevent cortisone-induced skin problems and supports skin health.

Pharmaceutical care in transplantation faces challenges but has promising future opportunities for better outcomes.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

Certain microRNAs may protect against hair loss in alopecia areata and could be potential treatment targets.

Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.

New treatments for alopecia areata show promise in improving hair loss outcomes.